SMARCA4-mutant solid tumors
Prelude Therapeutics Inc. supports clinical research in advanced or metastatic solid tumors with a focus on SMARCA4 mutation-driven disease, including non-small cell lung cancer, esophageal cancer, and other refractory solid malignancies.
- SMARCA4-mutant cancer
- Non-small cell lung cancer
- Esophageal and gastroesophageal junction cancer
- Metastatic solid tumors
The sponsor’s oncology portfolio includes studies centered on molecularly defined tumors and treatment-resistant disease across multiple thoracic and gastrointestinal cancers.
Hematologic malignancies
Its research activity also extends to relapsed and refractory hematologic malignancies, with interest in leukemias and lymphomas spanning both myeloid and lymphoid cancers.
- Acute myeloid leukemia
- Chronic lymphocytic leukemia
- Myelodysplastic syndrome
- Non-Hodgkin’s lymphoma
Areas of interest include mantle cell lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, and T-cell lymphoma subtypes, reflecting a broad focus on difficult-to-treat blood cancers.
Myeloid disorders and overlap syndromes
The sponsor is involved in studies of myelodysplastic syndrome, chronic myelomonocytic leukemia, and MDS/MPN overlap syndrome, indicating attention to disorders at the intersection of marrow failure and proliferative disease.
- Chronic myelomonocytic leukemia
- MDS/MPN overlap syndrome
- Myelodysplastic syndrome
- Myeloproliferative neoplasm
These programs align with research in bone marrow-related malignancies and genetically defined hematologic disease.
Targeted oncology combinations
Prelude Therapeutics Inc. also funds research combining targeted agents with established oncology therapies in both solid and blood cancers, including combinations relevant to immune checkpoint inhibition and B-cell malignancies.
- Advanced solid tumors
- Relapsed/refractory lymphoma
- Leukemia and lymphoma combinations
- Molecularly targeted cancer therapy
Its trial portfolio spans cancers such as breast cancer, bladder cancer, pancreatic cancer, ovarian cancer, and head and neck squamous cell carcinoma.
